NEW YORK (GenomeWeb News) – Illumina said this week that its board has authorized the repurchase of up to $250 million of the company's common stock. The new repurchase program is in addition to Illumina's current program, which has $117.5 million available for share repurchases.


The US Food and Drug Administration confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review Exact Sciences' premarket approval application for the Cologuard colorectal screening test on March 27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.